

Publications (only since 1995- previous omitted):

102. Vieira, L., Slotki, I.N. and Cabantchik, Z.I. (1995). Chloride conductive pathways which support electrogenic H-pumping in Leishmania major promastigotes. *J. Biol. Chem.* 270:5299-5304
103. Vieira, L. and Cabantchik, Z.I. (1995). Bicarbonate ions and pH regulation of Leishmania major promastigotes. *FEBS Lett.* 36:123-126.
104. Tsafack, A., Golenser, J., Libman, J., Shanzer, A. and Cabantchik, Z.I. (1995). Mode of action of iron(III) chelators as antimalarials. Overadditive effects in the combine action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. *Mol. Pharmacol.* 47:403-409.
105. Cabantchik, Z.I. (1995). Iron chelators as antimalarials. The biochemical basis of cytotoxicity. *Parasitol. Today* 11:74-78. (invited review).
106. Breuer, V.W., Epsztejn, S., Milgram, P. and Cabantchik, Z.I. (1995). Transport of iron and other related metals into cells as revealed by a fluorescent probe. *Am. J. Physiol (Cell)* 268:1354-1361.
107. Golenser, J., Chevion, M. and Cabantchik, Z.I. (1995). Malaria, iron and oxidant stress. In Parasitology for the 21st century: ICOPA VIII. M.A. Ozcel and Alkan (editors). pp 89-102, CAB International, Wallingford, Oxon, UK. (invited review).
108. Vieira, L. and Cabantchik, Z.I. (1995). Amino acid uptake and intracellular accumulation Leishmania major promastigotes are largely determined by a H-pump generated membrane potential. *Mol. Biochem. Parasitol.* 75:15-23.
109. Cabantchik, Z.I., Milgram, P., Glickstein, H. and Breuer, W., (1995) A method for assessing iron chelation in membrane model systems and in living mammalian cells. *Anal. Biochem.* 233:221-227.
110. Breuer VW, Epsztejn S, Cabantchik ZI. (1995) Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron. *J. Biol. Chem.* 270:24209-16.
111. Glickstein, H., Loyevsky, M., Konijn, A., Libman, J., Shanzer, A. and Cabantchik, Z.I. (1996) Differential cytotoxicity of iron chelators in proliferation of malaria infected cells versus mammalian cells. *Blood.* 87:4871-4878
112. Cabantchik Z.I., Golenser J, Loyevsky M, Tsafack A. (1996) Iron chelators. Mode of action as antimalarials. *Acta Haematol* 95:70-77.
113. Tsafack, A., Golenser, J. and Cabantchik, Z.I. (1996). Antimalarial action of iron chelators. In Molecular Biology of Hematopoiesis. N. Abrams, Editor.
114. Breuer, W., Epsztejn, S. and Cabantchik, Z.I., (1996) The dynamics of the labile iron pool of mammalian cells. *FEBS Letters* 382:304-308.
115. Tsafack, A., Loyevsky, M., Ponka, P. and Cabantchik, Z.I. (1996). Mode of action of iron chelators as antimalarials. The combined action of desferrioxamine and aryl-isonicotinoyl-hydrazones. *J. Lab. Clin. Med.* 127:574-582.
116. Vieira, L. and Cabantchik, Z.I. (1996). An amino acid channel activated by hypotonically swelling of Leishmania major promastigotes. *Biochem. J.* 319: 691-697.
117. Tsafack, A., Libman, J., Shanzer, A. and Cabantchik, Z.I. (1996). Chemical determinants of the antimalarial activity of reversed siderophores. *Antimicrob. Ag. Chemother.* 40(9): 2160-2166.
118. Epsztejn, S., Kakhlon, O., Breuer, W., Glickstein, H. and Cabantchik, Z.I., (1997) A fluorescence assay for the labile iron pool (LIP) of mammalian cells. *Anal. Biochem.* 248:31-40.
119. Breuer, W., Greenberg, E. and Cabantchik, Z.I. (1997). The role of newly delivered transferrin iron in oxidative cell injury. *FEBS Lett.* 403:213-219.
120. Zanninelli, G., Brissot, P., Hider, R.R., Konijn, A.P., Shanzer, A. and Cabantchik, Z.I. (1997). Chelation and mobilization of cellular iron by different classes of iron chelators. *Mol. Pharmacol.* 51: 842-852.
121. Vieira, L. and Cabantchik, Z.I. (1997). Modulation of the swelling-activated amino acid channel of Leishmania major promastigotes by protein kinases. *Mol. Biochem. Parasitol.* 90: 449-461.
122. Golenser, J., Domb, A., Teomim, B., Tsafack, A., Nissim, O., Ponka, P., Eling, W. and Cabantchik, Z.I. (1997). The treatment of animal models of malaria with iron chelators using a novel polymeric device for slow drug release. *J. Pharmacol. Exp. Ther.* 281:1127-1135.
123. Picard, V., Epsztejn, S., Santambrogio, P., Cabantchik, Z.I. and Beaumont C. (1998). Role of ferritin in the control of the labile iron pool in murine erythroleukemic cells. *J. Biol. Chem.* 273:15382-15386.

124. Konijn, A.M., Vaisman, B., Glickstein, H., Meyron-Holtz, E., Slotki, I.N. and Cabantchik, Z.I. (1999). The cellular labile iron pool (lip) and intracellular ferritin in K562 cells. *Blood*. 94,2128-2134.
125. Epsztejn, S. Picard. V, Breuer, W.V., Glickstein, H. Slotki, I.N., Beaumont C. and Cabantchik, Z.I. (1999). Functional consequences of H-ferritin over-expression in transfected cells.*Blood*. 94:3593-3603.
126. Cabantchik, Z.I. (1999). Erythrocyte membrane transport. In "Novartis Foundation Symposium 226-Jan. 1999 on Transport and trafficking in the malaria-infected erythrocyte. J. Wiley & Sons. Chichester pp.6-19
127. Cabantchik, Z.I., Moody-Haupt, S. and Gordeuk, V. (1999). Iron chelators as anti-infectives. Malaria as a paradigm. *FEMS*. 26:289-298.
128. Cabantchik, Z.I., Slotki, I.N., Beaumont, C. and Breuer, W. (1999) Development and Application of Fluorescent Assays for Probing Labile Iron Pools in Biological Systems. In: "Iron Chelators: New Development Strategies" (D. Badman, R.J. Bergeron and G.M. Brittenham, eds), Saratoga Publishing Group, Ponte Vedra, Florida).
129. Breuer, W., and Cabantchik, Z.I. (2000). The importance of non-transferrin bound iron in disorders of iron metabolism. *Transf. Sci*. 23:185-1
130. Breuer, W., Ronson, A, Slotki, I.N., Abramov, A., and Cabantchik, Z.I. (2000). The application of a novel method for assessing non transferrin bound iron (NTBI) in pathological conditions. *Blood* 95:2975-2982.
131. Breuer, W.V. and Cabantchik, Z.I (2001). A fluorescence-based one-step assay for serum non-transferrin bound iron (NTBI).*Anal. Biochem*. 299:194-202.
132. Kakhlon, O. Gruenbaum. Y.and Cabantchik, Z.I (2001). Repression of the heavy ferritin chain increases the labile iron pool of human K562 cells *Biochem. J*. 356: 311-316.
133. Kakhlon, O. Gruenbaum. Y.and Cabantchik, Z.I (2001). Repression of ferritin expression increases the labile iron pool and ,oxidative stress ,and short-term growth of human erythroleukemia cells. *Blood*. 97:2863-2871.
134. Esposito, B.P, Breuer, V.W., Slotki, I.N. and Cabantchik, Z.I.(2002). Labile iron in parenteral iron formulations and its potential for generating plasma non-transferrin bound iron (NTBI) in dialysis patients. *Eur. J. Clin. Inv*. 1:42-9.
135. Espósito, B.P., Epsztejn, S. Breuer, W. Cabantchik, Z.I. (2002) A review of fluorescence methods for assessing labile iron in cells and biological fluids. *Anal. Biochem*. 1;304(1):1-18.
136. Cabantchik(2002). Intracellular and extracellular labile iron pools. *Adv Exp Med Biol*. 509:55-75. Review
137. Esposito BP, Breuer W, Cabantchik ZI. (2002). Design and applications of methods for fluorescence detection of iron in biological systems. *Biochem Soc Trans*. 30(4):729-32.
138. Kakhlon O, Cabantchik ZI. (2002) The labile iron pool: characterization, measurement, and participation in cellular processes . *Free Radic Biol Med*. 3(8):1037-46. Review.
139. Meijler MM, Arad-Yellin R, Cabantchik ZI, Shanzer A. (2002). Synthesis and evaluation of iron chelators with masked hydrophilic moieties. *J Am Chem Soc*. 124:12666-12667.
140. Esposito, BP., Breuer, W., Sirankapracha, P. Pootrakul, P., Hershko, C. and Cabantchik, Z.I. (2003). Labile plasma iron in iron overload: redox activity and susceptibility to chelators.*Blood*. 2003;102: 2670-2677.
141. Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha P., Hershko, C. and Cabantchik, Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator. *Blood* 104: 1504 – 1510 .
142. Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A, Miller-Lotan R, Hammerman H, Levy AP. (2004), Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. *Diabetes Care*. 2004 Nov;27(11):2730-2.
143. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M.(2005). Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents

- for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. *Bioorg Med Chem.* 13):773-83.
144. Cabantchik ZI and Breuer, W. (2005). LPI-Labile plasma in iron overload. *Best Practice & Research in Clinical Haematology* Vol. 18, No. 2, pp. 277–287.
 145. Hershko, C., Konijn, A.M. and Cabantchik, Z.I. (2005). Iron chelation therapy. *Current Hematol. Reports* Vol. 18, No. 2, pp. 277–287.
 146. Le Lan, c , O Loréal T Cohen, M Ropert, H Glickstein, M Pouchard, Y Deugnier, A Le Treut,W Breuer, ZI Cabantchik, P Brissot (2005). Association between hepatic damage, iron overload and incidence of redox-active iron in the plasma. *Blood.* 105: 4527-4531
 147. Glickstein, H, Ben El , R., Shvartsman M. and and Z. loavCabantchik (2005). Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. *Blood.* 106: 3242-3250
 148. Hershko, C, Link, G, Konijn AM and Cabantchik. Z.I. (2005). *Iron Chelation Therap. Curr, Hematol.* 4:110-116
 149. van der A, D.J.; Marx, JJM, Grobbee, DE, Kamphuis, MH; Georgiou, N; van Kats-Renaud, JH; Breuer, W., Cabantchik, Z.I.; Roest, M, Voorbij, HAM; van der Schouw, YH (2006) Non-Transferrin-Bound Iron and Risk of Coronary Heart Disease in Postmenopausal Women Circulation. *Cardiology* 113:1942-1949.
 150. Rachmilewitz E.A, Weizer-Stern, O., Adamsky, K., Amariglio N., Rechavi, R., Brda, L., Rivella S. and Cabantchik, Z.I.(2005).Role of Iron in Inducing Oxidative Stress in Thalassemia: Can It Be Prevented by Inhibition of Absorption and by Antioxidants? *Ann. N.Y. Acad. Sci.* 1054: 118–123.
 151. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko, C, Nick H and Cabantchik ZI (2006). Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. *Blood* 108:3195-3203.
 152. Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, Rachmilewitz E, Breda L, Rivella S, Cabantchik ZI, Rechavi G. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. *Br J Haematol.* 2006;135:129-138.
 153. Boddaert, N., Le-Quan-Sang, K.H., Rötig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi,D., Thalabard, J.C., Munnich, A. and Cabantchik, Z.I. (2006). Iron chelation treatment evokes a reduction of MRI R2* values in a brain area implicated in Friedreich's ataxia (2007). *Blood.* 110: 401-408
 154. Mazariegos DI, Cabantchik ZI, Cassels BK Núñez MT (2006) Characterization of mitochondrial iron uptake in HepG2 cells *Biol Res* 39: 199-201
 155. Gardenghi, S., Marongiu, M.F., Ramos, P., Guy, E., Breda, L., Chadburn, A., Liu, Y.F., Amariglio, N., Rechavi, G., Rachmilewitz, E.A., Breuer, W., Cabantchik, Z.I., Wrighting, D.M., Andrews, N.A., de Sousa, M., Giardina, P.J., Grady, R.W. and Rivella, S. (2007). Ineffective erythropoiesis in β -thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. *Blood.* 109: 4599-4606.
 156. Shvartsman M, Kikkeri, R, Shanzer A, Cabantchik ZI (2007).Iron accesses mitochondria from a cytosolic pool of non-labile iron. Biological and clinical implications. *Am J Physiol Cell Physiol* 293: C1383-C1394
 157. Hershko, C., Ronson, A., Soroujourn, M., Patz, J. and Z.I. Cabantchik (2007). Mechanism of iron regulation and of iron deficiency. *Haematologica.*92:583-588
 158. Breuer, W., Shvartsman, M., Cabantchik, Z.I. (2007) Intracellular labile iron. A review. *Int J Biochem Cell Biol.* . 40: 350-354
 159. Sung, Y.S., Breuer W, Munnich , A. , Cabantchik ZI. (2008) Redistribution of accumulated cell iron. A modality of chelation with therapeutic implications. *Blood.* 111:1690-1699
 160. Zanninelli, G., Breuer, W. and Cabantchik, Z.I. (2009). Daily labile plasma iron as an indicator of chelator activity in Thalassemia major patients. *Br. J. Hematol.* 147, 744–751
 161. Kakhlon, O., Manning, H., Breuer, W, Cortopassi, G., Munnich , A. , Cabantchik ZI. (2008). Cell functions impaired by frataxin deficiency are restored by iron relocation. *Blood.* 112:5219-27.

162. Breuer W, Cabantchik I. (2009) Disorders affecting iron distribution: causes, consequences and possible treatments, *BloodMed.com*. <http://www.bloodmed.com/800000/mini-reviews1.asp?id=253&p=1&v=1>
163. Cabantchik Z.I., Fibach, E. and Bruer, W. 2009. Can labile plasma iron (LPI) and labile cell iron (LCI) levels serve as early indicators of chelation efficacy in iron overload? *BloodMed.com*. Retrieved July 15 2009. <http://www.bloodmed.com/800000/mini-reviews1.asp?id=254>
164. Ginzburg, Y.Z., Rybicki, A.C., Suzuka, S.M., Hall, C.B., Breuer, W., Cabantchik, Z.I., et al. (2009). Exogenous iron increases hemoglobin in beta-thalassemic mice. *Experimental Hematology*, 37, 172–183.
165. Li, H., Rybicki, A.C., Suzuka, S.M., von Bonsdorff, L., Breuer, W., Hall, C.B., Cabantchik, Z.I., Ginzburg, Y.Z. (2010). Transferrin injections ameliorate disease in β -thalassemic mice. *Nature Med.* published online 24 January 2010; doi:10.1038/nm.2073
166. Kakhlon, O., Breuer, W, Munnich, A. and Cabantchik ZI.(2010). Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. *Can. J. Physiol. Pharmacol.* 88:187-196 (invited review).
167. Shvartsman, M., Fibach, E. and Cabantchik, Z.I. (2010). Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence. *Biochem. J.*429:185–193.
168. Sohn, YS, Mitterstiller, AM, Breuer, W, Weiss, G and Cabantchik, Z.I (2010) Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. *Br. J. Pharmacol.* DOI: 10.1111/j.1476-5381.2010.01120.x
169. Kakhlon, O., Breuer, W, Munnich, A. and Cabantchik ZI.(2011). Neurological disorders associated with iron misdistribution: The therapeutic potential of siderophores. In Gadoth, N. & Goebel, H. (Eds.). "Oxidative Stress and Free Radical Damage in Neurology"- Chapter 11, Springer Verlag, New York. pp 169-190. Volume:
170. Pennell, D.J., Carpenter, J.P., Roughton, M., and Cabantchik, Z.I. (2011). On improvement in ejection fraction with Iron Chelation in Thalassemia Major and the risk of future heart failure. *Journal of Cardiovascular Magnetic Resonance*. doi:10.1186/1532-429X-13-45
171. Breuer, W., Ghoti, H., Shattat, A., Goldfarb, A., Koren, A., Levin, C. Rachmilewitz, E. and Cabantchik, Z.I (2012) Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients. *Am. J. Hematol.* 87:55–61.
172. Zurisa, J.A., Harir, Y., Conlan, A.R., Shvartsman, M., Michael, D., Tamir, S., Paddock, M.L., Onuchica, J.N., Mittler, R., Cabantchik, Z.I., Jennings, P.A., Nechushtai, R. (2011). Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein. *Proc. Nat. Acad. Sci.* 108: 13047–13052
173. Sohn, Y.S., Ghoti, H., Breuer, W., Rachmilewitz, E.A., Attar, S, Weiss, G. and Cabantchik, Z.I. (2012) The role of endocytic pathways in cellular uptake of plasma non-transferrin iron. *Haematologica* 97:670-678. doi:10.3324/haematol. 2011.054858.
174. Shvartsman, M. and Cabantchik, Z.I. (2012) Intracellular iron trafficking. Role of cytosolic ligands. *Biomaterials* (2012) 25:711–723 DOI 10.1007/s10534-012-9529-7
175. Nechushtai R, Conlan AR, Harir Y, Song L, Yogevev O, Eisenberg-Domovich Y, Livnah O, Michaeli D, Rosen R, Ma V, Luo Y, Zuris JA, Paddock ML, Cabantchik ZI, Jennings PA, Mittler R. (2012). Characterization of Arabidopsis NEET Reveals an Ancient Role for NEET Proteins in Iron Metabolism. *Plant Cell*. 24:2139-2154.
176. Cabantchik, ZI, Sohn, Y-S, Breuer, W, Espósito, BP (2013). The molecular and cellular basis of iron toxicity in Iron Overload (IO) disorders. Diagnostic and therapeutic approaches. Invited review. *Thalassemia Rep.* 3(s1):e3 7-13.
177. Tamir, S. Zuris, JA, Agranat, L, Lipper, CH, Conlan, AR, Michaeli, D, Harir, Y, Paddock, ML, Mittler, R, Cabantchik, ZI, Jennings, PA, Nechushtai, R (2013). Nutrient-Deprivation Autophagy Factor-1 (NAF-1): Biochemical Properties of a Novel Cellular Target for Anti-Diabetic Drugs. *PLoS One* 8(5): e61202. doi:10.1371/journal.pone.0061202.

178. Sohn, Y-S, Tamir, S., Song, L, Michaeli, D, Matouk, I, Shulaev, V, Paddock, ML, Hochberg, A, Cabantchik, ZI, Onuchic, J, Jennings, PA, Nechushtai, R, Mittler, R, (2013) NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. *Proc Natl Acad, Sci USA*. 110:14676-14681.
179. Cabantchik, Z.I. et al. (2013). Regional siderosis: a new challenge for iron chelation therapy. *Front. Pharmacol.*, | doi: 10.3389/fphar.2013.00167
180. Devos, D., Moreau, C., Dujardin, K., Cabantchik, Z.I., Defebvre, L., and Bordet, R. (2013). New Pharmacological Options for Treating Advanced Parkinson's Disease. *Clinical Therapeutics*. 35:1640-1652.
181. Devos, D., Moreau, C., Devedjian, Kluza, J., Laloux, C., Jonneaux, A., Petraut, M., Ryckewaert, G., Garçon, G., Rouaix, G., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdhaus, V. Sablonnière, B., Strubi-Vuillaume, I., Zahr, N., Destée, Corvol, J.C., Pörtl, D., Leist, M., Rose, C., Defebvre, L., Marchetti, P., Cabantchik, Z.I. and Bordet, R (2013) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. *Antioxidants & Redox Signaling*. ahead of print. doi:10.1089/ars.2013.5593.
182. Danjou, F., Cabantchik, Z.I., Origa R., Barella, S., Defraia, E. et al. (2014) A decisional algorithm to start iron chelation in patients with beta thalassemia. *Haematologica*; ; 99(3): e38–e40.
183. Cabantchik, Z.I. (2014). Labile iron in cells and body fluids. *Physiology, Pathology and Pharmacology. Nature Front. Pharmacol* 4:1 <http://journal.frontiersin.org/Journal/10.3389/fphar.2014.00045/full>
184. Chen M-p, Cabantchik ZI, Chan S, Chan GC-f, Cheung Y-f (2014) Iron Overload and Apoptosis of HL-1 Cardiomyocytes: Effects of Calcium Channel Blockade. *PLoS ONE* 9(11): e112915. doi:10.1371/journal.pone.01129.
185. Tamir, S., Paddock, M/L/, Darash-Yahana-Baram, M. et al. (2015), Structure–function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease, *Biochim. Biophys. Acta Rev. Biomembranes* 1853:1294–1315 dx.doi.org/10.1016/j.bbamcr.2014.10.014
186. Cabantchik Z.I. and Rachmilewitz, E. (2015). Labile Iron: Potential Toxicity in Iron Overload Disorders. *The Hematologist*. 12: 6
187. Grolez, G., Moreau, C., Sablonnière, B., Garçon, Devedjian, J.C., Kluza, Meguig, S., Gele, P., Delmaire, C., Bordet, R., Defebvre, L., Cabantchik, Z.I. and Devos, D., (2015) Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease *BMC Neurology* doi:10.1186/s12883-015-0331-
188. Slotki, I.N. and Cabantchik, Z.I. (2015). The Labile Side of Iron Supplementation in CKD *J Am Soc Nephrol* 26: 000–000, 2015. doi: 10.1681/ASN.2015010052
189. Berdoukas V, Coates TD, Cabantchik ZI. [Iron and oxidative stress in cardiomyopathy in thalassemia](http://dx.doi.org/10.1016/j.freeradbiomed.2015.07.019). *Free Rad Biol Med*. 2015 Jul 26. pii: S0891-5849(15)00343-3. doi: 10.1016/j.freeradbiomed.2015.07.019. [Epub ahead of print] Review.
190. Cabantchik ZI, Drakesmith H, From one Nobel Prize (P. Ehrlich) to another (Tu Youyou): 100 years of chemotherapy of infectious diseases, *Clinical Microbiology and Infection* (2015), <http://dx.doi.org/10.1016/j.cmi.2015.11.011>
191. Holt, S.H., Darash-Yahana, M., Sohn, YS, Song, L., Karmi, O, Tamir, S. et al (2015) Activation of Apoptosis in NAF-1-Deficient Human Epithelial Breast Cancer Cells. *J Cell. Sci*. doi: 10.1242/jcs.178293.
192. Cabantchik ZI (2016). In search for symbolic qualities of iron, the metal of life. *Frontiers in Pharmacology* 7, DOI=10.3389/fphar.2016.00220.
193. Danielpur L., Sohn Y-S, Karmi O., Fogel C., Zinger A., Abu-Libdeh A., Israeli, T. Riahi, Y., Pappo, O., Birk, R., Zangen, D.H., Mittler, R., Cabantchik Z.I., Cerasi E., Nechushtai R. and Leibowitz G. (2016). GLP-1-RA corrects mitochondrial labile iron accumulation and improves β -cell function in type 2 Wolfram syndrome. *J Clin Endocrinol Metab* doi: 10.1210/jc.2016-2240.
194. Shemer, OS, Yacobovich, J, Cohen, M, Cabantchik ZI, Tamary H. (2018) Labile plasma iron as an indicator of patient adherence to iron chelation treatment. *Blood Cells, Molecules, and Disease*. doi:10.1016/j.bcmed.2018.01.001.

195. Devos D et al (2018) Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? *Antioxid Redox Signal*. 2017 Dec 29. doi: 10.1089/ars.2017.7493. [Epub ahead of print].
196. Moreau, C., Duce, J. A., Rascol, O., Devedjian, J.-C., Berg, D., Dexter, D., Cabantchik, Z. I., Bush, A. I., Devos, D. and the FAIRPARK-II study group (2018), Iron as a therapeutic target for Parkinson's disease. *Mov Disord*. 33: 568-572 <https://doi.org/10.1002/mds.27275>. doi:10.1002/mds.27275.
197. Mittler R¹, Darash-Yahana M², Sohn YS², Bai F³, Song L¹, Cabantchik IZ², Jennings PA⁴, Onuchic JN³, Nechushtai R². (2018). NEET Proteins: A New Link Between Iron Metabolism, Reactive Oxygen Species, and Cancer . *Antioxid Redox Signal*. . doi: 10.1089/ars.2018.7502. [Epub ahead of print].
198. Steinberg-Shemer O_, Yacobovich J_, Cohen M_, Cabantchik IZ_, Tamary H_ (2018). Labile plasma iron as an indicator of patient adherence to iron chelation treatment. *Blood Cells, Molecules & Diseases* 71:1-4. DOI: 10.1016/j.bcmed.2018.01.001.
199. Adams, P. et al., Altes, A., Brissot, P. et al (2018). Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype. *Hepato Int*. 2018 Mar; 12(2): 83–86. Published online 2018 Mar 27. doi: 10.1007/s12072-018-9855-0
200. Kaplan, A., , A., Zelicha, H., Tsavan A., Yasoloka-Meir, A., Kovsan, J., Novack, L., Ceglatak, U., Burckhardt, R., Willenberg, A., Tirosh, A., Cabantchik, I., Stmpfer, M.J. and Shai, I/ 2018 Protein bioavailability of Wolffia globosa duckweed, a novel aquatic plant, – a randomized controlled trial. *Clin.; Nutr*. 2018. DOI: <https://doi.org/10.1016/j.clnu.2018.12.009>

Patents (since 1995):

1. Novel chelators as therapeutic agents for malaria and for siderosis (jointly with A. Shanzer) (1995)
2. Novel means for drug administration using subcutaneous polymeric patches: application to malaria and siderosis (jointly with A. Domb and J. Golenser).(1996).
3. The assay of non-transferrin iron (NTBI) and other metals in metal overload (together with W. Breuer) (1998)